The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season: Paris Tuesday, June 10, 2025, 11:00 Hrs [IST] Sanofi is shipp ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Investing.com -- Shares of Swedish Orphan Biovitrum (STO:SOBI) fell by 4% today after the FDA approved Merck (NSE: PROR )’s respiratory syncytial virus (RSV) vaccine Enflonsia (clesrovimab), which ...

HHS Secretary Robert F. Kennedy Jr. abruptly removed 17 vaccine experts from the CDC’s Advisory Committee on Immunization ...

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...